Why monitor the neonatal brain-that is the important question
Vanhatalo, Sampsa; Stevenson, Nathan J; Pressler, Ronit M; Abend, Nicholas S; Auvin, Stéphane; Brigo, Francesco; Cilio, M Roberta; Hahn, Cecil D; Hartmann, Hans; Hellström-Westas, Lena; Inder, Terrie E; Moshé, Solomon L; Nunes, Magda L; Shellhaas, Renée A; Vinayan, Kollencheri P; de Vries, Linda S; Wilmshurst, Jo M; Yozawitz, Elissa; Boylan, Geraldine B
(2023) Pediatric Research, volume 93, issue 1, pp. 19 - 21
(Comment)
Abstract
A key goal of neonatal neurocritical care is improved outcomes, and brain monitoring plays an essential role. The recent NEST trial reported no outcome benefits using aEEG monitoring compared to clinical seizure identification among neonates treated for seizures. However, the study failed to prove the effects of monitoring on seizure
... read more
treatment in the first place.
show less
Download/Full Text
Keywords: Pediatrics, Perinatology, and Child Health, Journal Article
ISSN: 0031-3998
Publisher: Lippincott Williams & Wilkins
Note: Funding Information: S.V. is an unpaid advisor for Stratus and ANT. R.M.P. is an investigator for studies with UCB and does consultancy work for Kephala LTD, Ireland. She served as a Speaker and/or on Advisory Boards for Natus, GW, Eisai, and UCB. G.B.B. has a consultancy with UCB and Nihon Kohden to provide advice on neonatal EEG monitoring. She is a co-founder of a start-up company Kephala LTD, which provides EEG reviewing services for industry and academia. M.R.C. serves as a Speaker and/or on Advisory Boards for Eisai, UCB, and Biocodex, and does consultancy work for Sanofi Aventis. J.M.W. receives an honorarium for her role as Associate Editor for Epilepsia, advisory board for South African branch of Sanofi. S.A. receives an honorarium for his role as associate Editor for Epilepsia. He has served as consultant or received honoraria for lectures from Angelini Pharma, Biocodex, Biomarin Encoded, Eisai, GRINtherapeutics, GW Pharma, Neuraxpharma, Nutricia, Orion, UCB Pharma, Ultragenyx, Xenon, Zogenix. He has been an investigator for clinical trials for Eisai, Marinus, Takeda, UCB Pharma, Xenon, and Zogenix. K.P.V. received an honorarium from Medlink Neurology and Dravet Syndrome Foundation. C.D.H. receives an honorarium for his role as Associate Editor of the Journal of Clinical Neurophysiology, and has consulted on clinical trial design and conduct for UCB Biopharma and Takeda Pharmaceuticals. R.A.S. receives royalties from UpToDate for authorship of topics related to neonatal seizures; serves as Associate Editor for Neurology; and is a consultant for the Epilepsy Study Consortium. Her research is supported by NIH and the Pediatric Epilepsy Research Foundation. S.L.M. is serving as Associate Editor of Neurobiology of Disease. He is on the editorial board of Brain and Development, Pediatric Neurology, Annals of Neurology, MedLink, and Physiological Research. He receives compensation from Elsevier for his work as Associate Editor in Neurobiology of Disease and from MedLink for his work as Associate Editor; and royalties from two books he co-edited. N.J.S., L.H.-W., L.S.d.V., N.S.A., and F.B. declare no competing interests. Funding Information: We thank the following organizations for supporting research of authors in this article: European Union’s Horizon 2020 programme, Finnish Academy (337788, 332017), Sigrid Juselius Foundation, National Health and Medical Research Council of Australia, National Institute of Health Research (NIHR; UK), the Evelyn Trust (UK), NIH U54 NS100064 and NS43209, U.S. Department of Defense (W81XWH-18-1-0612), the Heffer Family and the Segal Family Foundations, and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. The views expressed are those of the author(s) and not necessarily those of the funders.
(Peer reviewed)
